The effect of melatonin receptor agonist on patients with atopic dermatitis

The effect of melatonin receptor agonist on patients with atopic dermatitis - The effect of melatonin receptor agonist on atopic dermatitis

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009707

Enrollment

Registered

2013-01-07

Start date

2013-01-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic dermatitis

Interventions

Atopic dermatitis group with administration of Rozerem tablets (melatonin receptor agonist)8 mg for four weeks Atopic dermatitis group without administration of Rozerem tablets Healthy control group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with atopic dermatitis agree to the study

Exclusion criteria

Exclusion criteria: Patients regarded as inadequate

Design outcomes

Primary

Measure	Time frame
1.Disease severity 2.Melatonin concentration in saliva 3.Interview form	—

Countries

Japan

Contacts

Public ContactTomoya Watanabe

Yokohama City University Graduate School of Medicine Environmental Immuno-Dermatology

nabetomo0968@yahoo.co.jp045-787-2675

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026